Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1α eradicates gliomas

Cancer Gene Therapy

Volumn 13, Issue 4, 2006, Pages 428-435

  Sun, X ^a,b   Liu, M ^b   Wei, Y ^b   Liu, F ^b   Zhi, X ^b   Xu, R ^c   Krissansen, G W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

C6 glioma; Hypoxia; Hypoxia inducible factor 1; Von Hippel Lindau

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BCL 2; RECOMBINANT PROTEIN; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CARCINOGENIC ACTIVITY; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GENE THERAPY; GENE TRANSFER; GLIOMA; GLIOMA CELL; GROWTH INHIBITION; GROWTH RATE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; RAT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, ANTISENSE; GLIOMA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RATS; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

ANIMALIA; MUS MUSCULUS;

EID: 33645026059     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700907     Document Type: Article

References (44)

1. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist 1999; 4: 209-224.
2. Murata H, Tajima N, Nagashima Y, Yao M, Baba M, Goto M et al. Von Hippel-Lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells. Cancer Res 2002; 62: 7004-7011.
3. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S et al. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994; 54: 4845-4847.
4. Kuwai T, Kitadai Y, Tanaka S, Hiyama T, Tanimoto K, Chayama K. Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1alpha. Cancer Sci 2004; 95: 149-153.
5. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW et al. Indentification of the von Hippel-Lindau tumor suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999; 96: 12436-12441.
6. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999; 13: 1822-1833.
7. Krek W. VHL takes HIF's breath away. Nat Cell Biol 2000; 2: E1-E3.
8. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: Tumor hypoxia as a therapy target. Cancer Metastasis Rev 1998; 17: 187-194.
9. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor-1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-4308.
10. 2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
11. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2: 423-427.
12. Yu F, White SB, Zhao Q, Lee FS. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001; 98: 9630-9635.
13. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271: 17771-17778.
14. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998; 201: 1153-1162.
15. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529-32537.
16. D'Angelo G, Duplan E, Vigne P, Frelin C. Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1 α Pro-564 hydroxylation. J Biol Chem 2003; 278: 15406-15411.
17. Brown RC, Mark KS, Egleton RD, Huber JD, Burroughs AR, Davis TP. Protection against hypoxia-induced increase in blood brain barrier permeability: role of tight junction proteins and NFκB. J Cell Sci 2003; 116: 693-700.
18. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
19. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270: 19761-19766.
20. Kanno H, Saljooque F, Yamamoto I, Hattori S, Yao M, Shuin T et al. Role of the von Hippel-Lindau tumor suppressor protein during neuronal differentiation. Cancer Res 2000; 60: 2820-2824.
21. Kanno H, Shuin T, Yamamoto I, Ito S, Shinonaga M, Yoshida M et al. Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Cancer Res 1997; 57: 1035-1038.
22. Sun X, Kanwar JR, Leung E, Vale M, Krissansen GW. Overexpressed von Hippel-Lindau tumor suppressor protein synergizes with anti-sense hypoxia inducible factor-1α to eradicate lymphomas. Gene Therapy 2003; 10: 2081-2089.
23. Sun X, Leung E, Kanwar JR, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy 2001; 8: 638-645.
24. Sawada M, Nakashima S, Banno Y, Yamakawa H, Takenaka K, Shinoda J et al. Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells. Oncogene 2000; 19: 3508-3520.
25. Sur P, Sribnick EA, Wingrave JM, Nowak MW, Ray SK, Banik NL. Estrogen attenuates oxidative stress-induced apoptosis in C6 glial cells. Brain Res 2003; 971: 178-188.
26. Appel E, Kazimirsky G, Ashkenazi E, Kim SG, Jacobson KA, Brodie C. Roles of BCL-2 and caspase 3 in the adenosine A3 receptor-induced apoptosis. J Mol Neurosci 2001; 17: 285-292.
27. Schraml P, Hergovich A, Hatz F, Amin MB, Lim SD, Krek W et al. Relevance of nuclear and cytoplasmic von Hippel Lindau protein expression for renal carcinoma progression. Am J Pathol 2003; 163: 1013-1020.
28. Lee S, Chen DY, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA 1996; 93: 1770-1775.
29. Lee S, Neumann M, Stearman R, Stauber R, Pause A, Pavlakis GN et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 1999; 19: 1486-1497.
30. Lewis MD, Roberts BJ. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein. Oncogene 2003; 22: 3992-3997.
31. Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000; 95: 3403-3411.
32. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumour progression, metastasis and cancer therapy. Anti-Cancer Drugs 1995; 6: 3-18.
33. Qi H, Ohh M. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res 2003; 63: 7076-7080.
34. Massfelder T, Lang H, Schordan E, Lindner V, Rothhut S, Welsch S et al. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res 2004; 64: 180-188.
35. Bluyssen HA, Lolkema MP, van Beest M, Boone M, Snijckers CM, Los M et al. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett 2004; 556: 137-142.
36. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998; 1: 959-968.
37. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin Jr WG, Ohh M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 2004; 24: 3251-3261.
38. Davidowitz EJ, Schoenfeld AR, Burk RD. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 2001; 21: 865-874.
39. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998; 58: 4957-4962.
40. Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999; 19: 5902-5912.
41. Pioli PA, Rigby WFC. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein A2 and regulates its expression. J Biol Chem 2001; 276: 40346-40352.
42. Devarajan P, De Leon M, Talasazan F, Schoenfeld AR, Davidowitz EJ, Burk RD. The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J Biol Chem 2001; 276: 40599-40605.
43. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 2001; 61: 1768-1775.
44. Qi H, Gervais ML, Li W, DeCaprio JA, Challis JR, Ohh M. Molecular cloning and characterization of the von Hippel-Lindau-like protein. Mol Cancer Res 2004; 2: 43-52.